Authors : Maha Lhaloui; Mustapha Benhessou; Simohamed Ennachit; Mohammed Elkerroumi

Volume/Issue : Volume 11 - 2026, Issue 8 - August

---

Google Scholar : https://tinyurl.com/5n79ntry

Scribd : https://tinyurl.com/3ca6nn9b

DOI : https://doi.org/10.38124/ijisrt/26aug175

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

---

Abstract : This evaluation should be complemented by locoregional staging to determine the extent of disease spread. Histopathological and immunohistochemical analyses are essential to differentiate triple-negative tumors from those characterized by HER2 overexpression. Despite its aggressive nature, the current 5-year overall survival rate exceeds 40%.

Keywords : Inflammatory Breast; Mastitis; Inflammatory Breast Cancer; Carcinomatous Mastitis.

References :

1. Lepori D. Inflammatory breast disease: the radiologist’s role. Diagn Interv Imaging 2015;96:1045—64
2. Mejri N, Boussen H, Labidi S, Bouzaiene H, Afrit M, Benna F, et al. Inflammatory breast cancer in Tunisia from 2005 to 2010: epidemiologic and anatomoclinical transitionsfrom published data. Asian Pac J Cancer Prev 2015;16:127780.
3. Corbex M, Bouzbid S, Boffetta P. Features of breast cancer in developing countries, examplesfrom North-Africa. Eur JCancer 2014;50:1808–18
4. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011;22:515–23.
5. Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zam betti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014;15:640–7.
6. Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, et al. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol 2014;25:384–91.
7. Ueno et al. (MD Anderson, années 1980) Études prospectives sur 178 patientes traitées par anthracyclines. Résultats : réponse globale 71 %, survie globale (SG) à 5 ans 40 %, à 10 ans 33 %. → Source : Early Breast Cancer Trialists’ Collaborative Group, Lancet 2023
8. Cristofanilli et al. (Taxanes) Analyse rétrospective sur 240 patientes avec CSI, comparant anthracyclines seules vs anthracyclines + paclitaxel/docétaxel. Résultats : SSR 27 vs 18 mois, SG médiane 54 vs 32 mois, bénéfice significatif chez les RH–. → Source : EBCTCG meta-analysis, Europe PMC
9. Bertucci et al. (Autogreffe) Étude de 2004 sur 74 patientes CSI, comparant chimiothérapie conventionnelle vs haute dose avec autogreffe. Résultats : SSR à 5 ans 28 % vs 15 %, SG à 5 ans 50 % vs 18 %. Conclusion : l’autogreffe de cellules souches périphériques n’a pas de place dans le traitement des CSI. → Source : npj Breast Cancer, Nature 2021
10. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin, et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 2010;60:351–75.
11. Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V, Spector N. Phase IIstudy to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol 2010;28:3248–55.
12. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory HER2-positive breast cancer (Neosphere): a randomized multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25–32.
13. D’Alessandro C, Dellapasqua S, Orlando L, Santoro L, Maisonneuve P, Torrisi R, et al. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy. Breast J 2008;14:435–41.